The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations
Donald S. Silverberg(Tel Aviv Sourasky Medical Center), Adrian Iaina(Tel Aviv Sourasky Medical Center), David Brosh, Doron Schwartz, Itzhak Shapira, Tatyana Yachnin, Eyal Leibovitch, Shlomo Laniado, Miriam Blum, Shoshana Steinbruch, Carl Kaplan, Gad Keren, David S. Sheps(University of Florida), Dov Wexler, Ron Baruch, Dov Gavish, Bella Koifman
Cited by 729
Related Papers
Mood Disorders in the Medically Ill: Scientific Review and Recommendations
|Biological Psychiatry|2005|1.1k
Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial
|The Lancet|2000|1k
The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study
|Journal of the American College of Cardiology|2001|645
Randomised crossover trial of naltrexone in uraemic pruritus
|The Lancet|1996|298